Completed PHASE1 INTERVENTIONAL 1-arm NCT01637766

Intra-arterial Chemotherapy for Spinal Metastases (SIAC)

Selective Intra-arterial Chemotherapy in the Treatment Strategy of Metastatic Spinal Disease

Sponsor: Weill Medical College of Cornell University

Conditions Spinal Diseases Spinal Metastases Spinal Tumors

Interventions Melphalan (intra-arterial infusion)

Updated 8 times since 2017 Last updated: Jul 31, 2020 Started: Apr 30, 2012 Primary completion: Apr 30, 2018 Completion: Dec 31, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Spinal Diseases and Spinal Metastases and is currently completed. Weill Medical College of Cornell University leads this study, which shows 8 recorded versions since 2012 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Sep 2020 — Jan 2021 [monthly]

Completed PHASE1
Feb 2019 — Sep 2020 [monthly]

Completed PHASE1

Status: Recruiting → Completed

▶ Show 3 earlier versions

Jun 2018 — Feb 2019 [monthly]

Recruiting PHASE1
Feb 2017 — Jun 2018 [monthly]

Recruiting PHASE1
Jan 2017 — Feb 2017 [monthly]

Recruiting PHASE1

First recorded

Apr 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Weill Medical College of Cornell University

Data source: Weill Medical College of Cornell University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• New York, United States